━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TECHNOLOGY TRANSFER PACKAGE
P-13 — GREEN
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

**ONE-LINE OPPORTUNITY**
Technology: ML-based predictor using ICP + flow trends to forecast failure 24h before symptoms. Problem: Shunt failure prediction is reactive (symptoms then surgery). No predictive tool exists..

**BUYER PROBLEM**
Who: Hospital system / shunt OEM with clinical data access
Problem: Shunt failure prediction is reactive (symptoms then surgery). No predictive tool exists.
Current solution: Clinical monitoring (intermittent, reactive)
Why inadequate: Prediction accuracy on real patient data. Lead time in clinical setting.

**PROPOSED TECHNOLOGY**
ML-based predictor using ICP + flow trends to forecast failure 24h before symptoms

**WHY IT MAY MATTER**
Potential differentiation vs Clinical monitoring (intermittent, reactive): Prediction accuracy on real patient data. Lead time in clinical setting.

**CURRENT BEST ALTERNATIVE**
Clinical monitoring (intermittent, reactive)

**WHAT IS ACTUALLY DEMONSTRATED**

**WHAT IS ONLY MODELLED**
  - AUC >= 0.80 (not measured)
  - Lead time >= 12h (not measured)
  - T1. Model designed. NO real patient data tested. AUC and lead time are MODELLED, not measured.

**KNOWN FAILURES**
  - Conditional on P-15/P-16 energy (if those fail, P-13 has no power source)

**KEY DIFFERENTIATOR**
Potential differentiation vs Clinical monitoring (intermittent, reactive): Prediction accuracy on real patient data. Lead time in clinical setting.

**REMAINING DECISIVE UNCERTAINTY**
Prediction accuracy on real patient data. Lead time in clinical setting.

**DECISIVE EXPERIMENT**
Experiment: Retrospective: train on 100+ patient-years of shunt data. Test on held-out 20%.
Pass: AUC >= 0.80 AND lead time >= 12h on held-out cohort
Fail: AUC < 0.70
Cost: $5-15K (ESTIMATED: compute + data access)
Timeline: 2-4 weeks (ESTIMATED: data procurement + training)

**BUILD / INTEGRATION PATH**
MEDIUM — requires data pipeline + ML infrastructure

**REGULATORY STATUS**
SaMD (Software as Medical Device) — FDA 510(k) or De Novo

**IP / DILIGENCE STATUS**
Known IP: BUYER_DILIGENCE_REQUIRED — no patent search performed for this package
Diligence required: Full freedom-to-operate analysis by buyer counsel

**COMMERCIAL ROUTES**
License to hospital system or data company
(Options: LICENSE | BUILD | ACQUIRE | CO-DEVELOP | COMMISSION_EXPERIMENT | INTEGRATE | REJECT)

**BUYER'S NEXT ACTION**
COMMISSION TEST — obtain shunt patient dataset, train predictor, test on held-out cohort

**EVIDENCE MANIFEST**
Evidence ledger hash: 816e4eca4e861c6d...
BUYER_ACTION_ID: P13-EXP-001

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━